Canterbury DHB


AALL1732 Document

This is a paediatric protocol that is widely used for the AYA group of patients that are treated in haematology. Toxicity and dose modifications information all included.

AALL1732 AMD5 Inotuzumab Ozogamicin for Newly Diagnosed HR B-ALL

About this Canterbury DHB document (1178374):

Document Owner:

Not assigned (see Who's Who)

Last Reviewed:

December 2021

Next Review:

December 2024


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 1178374